title: [An early phase II clinical study of YM 294 (rhlL-11) in patients with solid tumors and malignant lymphoma].
abstract: An early phase II study was conducted to examine the efficacy and safety of YM 294 on chemotherapy-induced thrombocytopenia in patients with solid tumors and malignant lymphoma. The response rates which were judged as having good or excellent efficacy by the investigators were 66.7% in all groups with 25 microg/kg or more, and the increase in nadir platelet counts and decrease in platelet transfusions were observed. Adverse reactions were fever, edema, abnormal electrocardiogram and weight gain. All adverse reactions as well as abnormal changes in laboratory values for which the casual relationship with the study drug could not be excluded were resolved and proved to be not serious. The results of this study suggest the efficacy of YM 294 at 25 microg/kg or more for chemotherapy-induced thrombocytopenia in patients with solid tumors and malignant lymphoma. It was considered that a study should be performed to assess the efficacy and safety of YM 294 using a dose of 25 microg/kg or more in the future.
authors.affiliation: Dept of obstetrics and Gynecology, Kagoshima City Hospital.
authors.forename: Masayuki
authors.initials: M
authors.lastname: Hatae
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Ariyoshi
authors.forename: Masahiro
authors.initials: M
authors.lastname: Fukuoka
authors.forename: Kiyoyuki
authors.initials: K
authors.lastname: Furuse
authors.forename: Kiichirou
authors.initials: K
authors.lastname: Noda
authors.forename: Kouji
authors.initials: K
authors.lastname: Hirabayashi
authors.forename: Michiaki
authors.initials: M
authors.lastname: Yakushiji
authors.forename: Makoto
authors.initials: M
authors.lastname: Ogawa
authors.forename: Fumimaro
authors.initials: F
authors.lastname: Takaku
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004334:Drug Administration Schedule; D004487:Edema / Q000139:chemically induced; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005334:Fever / Q000139:chemically induced; D006801:Humans; D017370:Interleukin-11 / Q000009:adverse effects / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000188:drug therapy; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy; D010976:Platelet Count; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy*
chemical_list: D017370:Interleukin-11; D011994:Recombinant Proteins; D005047:Etoposide; D016190:Carboplatin; C105308:oprelvekin; D002945:Cisplatin